Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. (SVE) Price & Analysis
SVE Stock Chart & Stats
- Day’s Range
- PLN 2.64 - PLN 2.67
- 52-Week Range
- PLN 2.60 - PLN 4.25
- Previous Close
- PLN 2.65
- Volume
- N/A
- Average Volume (3M)
- 38.51K
- Market Cap
- PLN 200.69M
- Enterprise Value
- PLN 288.42T
- Total Cash (Recent Filing)
- PLN 350.00K
- Total Debt (Recent Filing)
- PLN 90.91M
- Price to Earnings (P/E)
- ―
- Beta
- 0.55
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
SVE FAQ
What was Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s price range in the past 12 months?
What is Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s market cap?
When is Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s upcoming earnings report date?
Is Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. overvalued?
Does Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. pay dividends?
What is Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s EPS estimate?
How many shares outstanding does Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. have?
Which hedge fund is a major shareholder of Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
Based in Lublin, Poland, Synthaverse S.A. operates as a pharmaceutical enterprise, engaging in the manufacturing and distribution of a broad spectrum of medicinal products, medical apparatus, and laboratory reagents throughout Poland. Its prescription drug portfolio encompasses Distreptaza, a medication prescribed in gynecology for addressing chronic inflammatory conditions of the uterine appendages and hemorrhoids. Other significant pharmaceuticals include Onko BCG 50 and BCG 100, formulated for the treatment of superficial (non-muscle invasive) bladder tumors; GAMMA anty HBs 200, utilized for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products essential for preventing hemolytic disease in fetuses and newborns; BioTrombina 400, designed for the topical management of severe bleeding; and the Anti-Tuberculosis Vaccine BCG 10, aimed at tuberculosis prevention. The company also supplies various medical devices, such as Ram blood for laboratory applications; Stonebrink medium for bovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium enriched with medicines for assessing Mycobacterium tuberculosis drug susceptibility; Löwenstein-Jensen medium containing glycerol, employed for the identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and as a lyophilisate; and rabbit plasma. Additionally, Synthaverse provides an extensive range of reagents, including horse, bovine, and calf serums, trypsin, PBS fluid, hanks fluid, parker's fluid, cell culture media like Eagle 1959, Rpmi 1640, and Ogawa medium, alongside pseudo cholinesterase, Ox fibrinogen, and rabbit complements. Originally established in 1944, the firm was formerly recognized as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. until its rebranding to Synthaverse S.A. in July 2023.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jakub Winkler
- Employees
- 214
- Website
- synthaverse.com
- Address
- Ul. Uniwersytecka 10, Lublin, LU, 20-029, PL
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |